Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, Uttar Pradesh, India.
Mini Rev Med Chem. 2021;21(12):1431-1456. doi: 10.2174/1389557521666201228145755.
Recently, a sudden outbreak of novel coronavirus disease (COVID-19) was caused by a zoonotic virus known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). It has caused pandemic situations around the globe affecting the lives of millions of people. So far, no drug has been approved for the treatment of SARS-CoV-2 infected patients. As of now, more than 1000 clinical trials are going on for repurposing of FDA-approved drugs and for evaluating the safety and efficiency of experimental antiviral molecules to combat COVID-19. Since the development of new drugs may require months to years to reach the market, this review focusses on the potential of existing small molecule FDA approved drugs and the molecules already in the clinical pipeline against viral infections like HIV, hepatitis B, Ebola virus, and other viruses of coronavirus family (SARS-CoV and MERS-CoV). The review also discusses the natural products and traditional medicines in clinical studies against COVID-19. Currently, 1978 studies are active, 143 completed and 4 posted results (as of June 13, 2020) on clinicaltrials.gov.
最近，一种新型冠状病毒病（COVID-19）的突然爆发是由一种称为严重急性呼吸综合征冠状病毒（SARS-CoV-2）的人畜共患病病毒引起的。它已在全球范围内造成大流行，影响了数百万人的生活。到目前为止，还没有批准用于治疗 SARS-CoV-2 感染患者的药物。截至目前，正在进行超过 1000 项临床试验，用于重新利用 FDA 批准的药物，并评估实验性抗病毒分子治疗 COVID-19 的安全性和有效性。由于开发新药可能需要数月甚至数年才能进入市场，因此，本综述重点关注现有小分子 FDA 批准药物和已经进入临床管道的针对 HIV、乙型肝炎、埃博拉病毒和其他冠状病毒家族（SARS-CoV 和 MERS-CoV）病毒的分子的潜力。本综述还讨论了针对 COVID-19 的临床研究中的天然产物和传统药物。目前，clinicaltrials.gov 上有 1978 项研究正在进行，143 项已完成，4 项已公布结果（截至 2020 年 6 月 13 日）。
